Holen Sie sich die Stockscreener-App
424.27
3.27%
13.45
Handel nachbörslich:
422.00
-2.27
-0.54%
Schlusskurs vom Vortag:
$410.82
Offen:
$410.29
24-Stunden-Volumen:
1.37M
Relative Volume:
1.01
Marktkapitalisierung:
$61.16B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-258.51
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+2.63%
1M Leistung:
+3.04%
6M Leistung:
+111.95%
1J Leistung:
+123.81%
1-Tages-Spanne:
$409.50
$432.83
1-Wochen-Bereich:
$383.76
$432.83
52-Wochen-Spanne:
$181.00
$437.41
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
424.27 | 61.16B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
704.15 | 260.36B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
234.07 | 164.55B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
181.48 | 51.16B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
476.88 | 46.85B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-23 | Eingeleitet | Roth Capital | Buy |
| 2026-09-09 | Fortgesetzt | UBS | Buy |
| 2026-09-08 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2026-06-26 | Fortgesetzt | Bernstein | Outperform |
| 2026-06-12 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2026-06-02 | Fortgesetzt | Wolfe Research | Outperform |
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results? - Zacks Investment Research
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Zacks Investment Research
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree. - The Motley Fool
Natera Co-Founder Sheena Jonathan Disposes of 3,150 Shares Under Rule 10b5-1 Plan on October 21, 2026 - Kalkine Media
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Natera Director Sheena Jonathan Files to Sell 9,450 Shares Valued at $3.88 Million - Kalkine Media
After a $7.01M September sale, a Natera (NTRA) director proposes another share sale. - Stock Titan
Natera Partners With TransCode to Advance Colorectal Cancer Trial - Zacks Investment Research
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Australia
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com Nigeria
Form 4 Natera Inc: Jonathan Sheena (Director, CO-FOUNDER) For: 16 October - Investing.com India
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? - Zacks Investment Research
Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Nigeria
Form 4 Natera Inc: Matthew Rabinowitz (Director, EXECUTIVE CHAIRMAN) For: 15 October - Investing.com Canada
Under a preset plan, Natera (NTRA)'s chairman sells 50,000 shares; he also exercises options. - Stock Titan
Natera Director Matthew Rabinowitz Files Form 144 to Sell 50,000 Shares Valued at $19.7M - Kalkine Media
$19.7M in Natera (NTRA) shares is proposed for sale following three September sales. - Stock Titan
Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million - GlobeNewswire Inc.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Tempus AI Expands Strategic Collaborations to Drive Future Growth - Zacks Investment Research
Matthew Rabinowitz Donates 6,000 Natera Shares to Charity on October 7, 2026 - Kalkine Media
Natera CEO Steven Chapman sells $526k in common stock By Investing.com - Investing.com UK
Natera CEO Steven Chapman sells $526k in common stock - Investing.com
Natera (NTRA) clinical diagnostics president sells 3,000 shares under a trading plan. - Stock Titan
Morgan Stanley Smith Barney is broker for a proposed 1,273-share sale at Natera (NTRA). - Stock Titan
After five sales in three months, a Natera (NTRA) officer proposes another stock sale. - Stock Titan
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com UK
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Australia
Form 4 Natera Inc For: 25 September By Investing.com - Investing.com Nigeria
Under a preset plan, two trusts sold 18,064 Natera (NTRA) shares in 12 transactions. - Stock Titan
Natera director Sheena’s trusts dispose of $7.0m in NTRA stock - Investing.com
Natera Director Sheena Jonathan to Offload 21,064 Shares Worth $8.16M, Form 144 Filed - Kalkine Media
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx - Zacks Investment Research
$8.2M stock sale planned at Natera (NASDAQ: NTRA) - Stock Titan
Natera (NASDAQ: NTRA) co-founder sells 9,150 shares under 10b5-1 plan - Stock Titan
Natera (NASDAQ: NTRA) chair unloads stock in preset plan - Stock Titan
Trust tied to Natera (NASDAQ: NTRA) eyes new stock sale after multimillion-dollar trades - Stock Titan
Understanding Momentum Shifts in (NTRA) - Stock Traders Daily
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - webull.com
Natera(NTRA.US) Officer Sells US$16.4 Million in Common Stock - Moomoo
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com South Africa
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - Investing.com
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com India
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - investing.com
Executive chair of Natera (NTRA) sells 50,000 shares - Stock Titan
Insider at Natera (NTRA) plans stock sale, with size detailed in new SEC notice - Stock Titan
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - simplywall.st
NTRA Maintains Buy Rating by UBS -- Price Target Raised to $435 - GuruFocus
3 Reasons Investors Love Natera (NTRA) - Yahoo Finance
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MICHAEL BROPHY | OFFICER |
Oct 28 '26 |
Proposed Sale |
410.82 |
1,222 |
502,022 |
0 |
| STEVEN CHAPMAN | OFFICER |
Oct 28 '26 |
Proposed Sale |
410.82 |
3,499 |
1,437,459 |
0 |
| JOHN FESKO | OFFICER |
Oct 28 '26 |
Proposed Sale |
410.82 |
917 |
376,722 |
0 |
| JONATHAN SHEENA | DIRECTOR |
Oct 28 '26 |
Proposed Sale |
410.82 |
191 |
78,467 |
0 |
| DANIEL RABINOWITZ | OFFICER |
Oct 28 '26 |
Proposed Sale |
410.82 |
988 |
405,890 |
0 |
| SOLOMON MOSHKEVICH | OFFICER |
Oct 28 '26 |
Proposed Sale |
410.82 |
1,185 |
486,822 |
0 |
| JONATHAN SHEENA | DIRECTOR |
Oct 27 '26 |
Proposed Sale |
404.90 |
287 |
116,206 |
0 |
| MICHAEL BROPHY | OFFICER |
Oct 27 '26 |
Proposed Sale |
404.90 |
771 |
312,178 |
0 |
| MATTHEW RABINOWITZ | DIRECTOR |
Oct 27 '26 |
Proposed Sale |
404.90 |
1,697 |
687,115 |
0 |
| DANIEL RABINOWITZ | OFFICER |
Oct 27 '26 |
Proposed Sale |
404.90 |
873 |
353,478 |
0 |
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):